Synthesis 2023; 55(13): 2047-2052
DOI: 10.1055/a-2016-4548
paper

Hexafluoroisopropanol-Induced Facial Selectivity in a Hindered Diels–Alder Reaction

Authors

  • David J. P. Kornfilt

    a   Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142, USA
  • Brian T. Chamberlain

    a   Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142, USA
  • Isabelle Chataigner

    b   Sorbonne Université, CNRS, Laboratoire de Chimie Théorique, LCT, 75005 Paris, France
    c   Normandie Université, UNIROUEN, CNRS, INSA Rouen, COBRA Laboratory, 76000 Rouen, France
  • Riccardo Spezia

    b   Sorbonne Université, CNRS, Laboratoire de Chimie Théorique, LCT, 75005 Paris, France
  • Florence F. Wagner

    a   Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142, USA

This work was funded by the Slim Initiative for Genomic Medicine in the Americas (SIGMA), a collaboration of the Broad Institute with the Carlos Slim Foundation.


Graphical Abstract

Preview

Abstract

BRD4780 is a small molecule that can selectively clear mutant MUC1-fs protein in mucin kidney disease models. Prior syntheses of BRD4780 were unsuitable for preparation on large scale. In this manuscript, HFIP is described as a unique solvent that allowed the key Diels–Alder reaction to proceed with >20:1 endo diastereoselectivity, enabling the kg-scale preparation of BRD4780 for further studies.

Supporting Information



Publication History

Received: 14 December 2022

Accepted after revision: 19 January 2023

Accepted Manuscript online:
19 January 2023

Article published online:
20 March 2023

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany